Skip to content

Clinical trials

Observational Asperger Syndrome trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Asperger Syndrome Phase: Observational Country / region: United States Clear all

16 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20041
20073
20082
20103
20121
20131
20152
20161
20171
20181

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed11
Active, not recruiting3
Recruiting1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Boston Children's Hospital3
Massachusetts General Hospital2
American Federation of Medical Synergetics1
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)1
Hoffmann-La Roche1
Icahn School of Medicine at Mount Sinai1
National Human Genome Research Institute (NHGRI)1
National Institute of Mental Health (NIMH)1
Rutgers University1
State University of New York - Upstate Medical University1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Asperger Syndrome16
Autistic Disorder13
Autism Spectrum Disorder11
Child Development Disorders, Pervasive7
Learning Disabilities3
Intellectual Disability2
Rett Syndrome2
Alzheimer Disease1
Attention Deficit Disorder with Hyperactivity1
Essential Tremor1

Trials

Showing 1 to 16 of 16. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.